| Kyle Thomas Johnson, MD | |
|
1021 Morehead Medical Dr, Ste 6100, Charlotte, NC 28204-2990 | |
| (980) 442-2000 | |
| Not Available |
| Full Name | Kyle Thomas Johnson |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Location | 1021 Morehead Medical Dr, Charlotte, North Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538659420 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 2023-01775 (North Carolina) | Primary |
| Entity Name | Carolinas Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275774333 PECOS PAC ID: 4789597477 Enrollment ID: O20031110000116 |
News Archive
A new drug to treat hepatitis C that costs $1,000 a pill has caused rising concern among insurers and state Medicaid programs. It has now also spurred interest from Democratic congressmen whose queries about the drug prompted a sell-off in biotechnology stocks on Friday. Three Democratic members of the House Energy and Commerce Committee have demanded that Gilead Sciences, the developer, justify the price of its drug, which is called Sovaldi (Pollack, 3/21).
DaVita Clinical Research (DCR), a specialty contract research organization with services spanning a broad spectrum of drug and device development, today announced an expansion of its clinical trials capabilities in Europe.
Halozyme Therapeutics, Inc. today announced the commencement of a Phase 1 clinical study that will assess the effects of three approved prandial (mealtime) insulin analogs administered with its proprietary rHuPH20 (PH20) hyaluronidase enzyme compared to each of the analogs alone. This randomized, three-way cross-over design, euglycemic clamp study will compare the postprandial pharmacokinetics (PK) and glucodynamics (GD) of the insulin analogs.
Researchers from this international study found that patients with chronic hepatitis B virus (HBV) infection who received at least 3 years of cumulative entecavir (antiviral) therapy achieved substantial histologic improvement and regression of fibrosis or cirrhosis. Full details of the study appear in the September issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).
The development of drugs to treat cognitive problems in patients with mental illness may be a step closer after a team of researchers discovered that an existing drug - used to treat constipation - may be able to boost our ability to think more clearly.
› Verified 5 days ago
| Entity Name | The Charlotte-mecklenburg Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669738829 PECOS PAC ID: 2961310685 Enrollment ID: O20100309000605 |
News Archive
A new drug to treat hepatitis C that costs $1,000 a pill has caused rising concern among insurers and state Medicaid programs. It has now also spurred interest from Democratic congressmen whose queries about the drug prompted a sell-off in biotechnology stocks on Friday. Three Democratic members of the House Energy and Commerce Committee have demanded that Gilead Sciences, the developer, justify the price of its drug, which is called Sovaldi (Pollack, 3/21).
DaVita Clinical Research (DCR), a specialty contract research organization with services spanning a broad spectrum of drug and device development, today announced an expansion of its clinical trials capabilities in Europe.
Halozyme Therapeutics, Inc. today announced the commencement of a Phase 1 clinical study that will assess the effects of three approved prandial (mealtime) insulin analogs administered with its proprietary rHuPH20 (PH20) hyaluronidase enzyme compared to each of the analogs alone. This randomized, three-way cross-over design, euglycemic clamp study will compare the postprandial pharmacokinetics (PK) and glucodynamics (GD) of the insulin analogs.
Researchers from this international study found that patients with chronic hepatitis B virus (HBV) infection who received at least 3 years of cumulative entecavir (antiviral) therapy achieved substantial histologic improvement and regression of fibrosis or cirrhosis. Full details of the study appear in the September issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).
The development of drugs to treat cognitive problems in patients with mental illness may be a step closer after a team of researchers discovered that an existing drug - used to treat constipation - may be able to boost our ability to think more clearly.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kyle Thomas Johnson, MD Po Box 19305, Charlotte, NC 28219-9305 Ph: () - | Kyle Thomas Johnson, MD 1021 Morehead Medical Dr, Ste 6100, Charlotte, NC 28204-2990 Ph: (980) 442-2000 |
News Archive
A new drug to treat hepatitis C that costs $1,000 a pill has caused rising concern among insurers and state Medicaid programs. It has now also spurred interest from Democratic congressmen whose queries about the drug prompted a sell-off in biotechnology stocks on Friday. Three Democratic members of the House Energy and Commerce Committee have demanded that Gilead Sciences, the developer, justify the price of its drug, which is called Sovaldi (Pollack, 3/21).
DaVita Clinical Research (DCR), a specialty contract research organization with services spanning a broad spectrum of drug and device development, today announced an expansion of its clinical trials capabilities in Europe.
Halozyme Therapeutics, Inc. today announced the commencement of a Phase 1 clinical study that will assess the effects of three approved prandial (mealtime) insulin analogs administered with its proprietary rHuPH20 (PH20) hyaluronidase enzyme compared to each of the analogs alone. This randomized, three-way cross-over design, euglycemic clamp study will compare the postprandial pharmacokinetics (PK) and glucodynamics (GD) of the insulin analogs.
Researchers from this international study found that patients with chronic hepatitis B virus (HBV) infection who received at least 3 years of cumulative entecavir (antiviral) therapy achieved substantial histologic improvement and regression of fibrosis or cirrhosis. Full details of the study appear in the September issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).
The development of drugs to treat cognitive problems in patients with mental illness may be a step closer after a team of researchers discovered that an existing drug - used to treat constipation - may be able to boost our ability to think more clearly.
› Verified 5 days ago
Mark J. Makhuli, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1225 Harding Pl, Ste 3100, Charlotte, NC 28204 Phone: 704-355-8686 | |
Dr. George Albert Dasher, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 10512 Park Rd, Suite 113, Charlotte, NC 28210 Phone: 704-541-8207 | |
Dr. Craig H Robson, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 335 N Caswell Rd, Charlotte, NC 28204 Phone: 704-384-7980 | |
Peter Earl Clark, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1021 Morehead Medical Dr, Ste 6100, Charlotte, NC 28204 Phone: 980-442-2000 | |
Jonathan Pierce Walker, MD Urology Medicare: Medicare Enrolled Practice Location: 1001 Blythe Blvd, Charlotte, NC 28203 Phone: 704-446-5070 | |
E Matthew Dilizia, MD Urology Medicare: Medicare Enrolled Practice Location: 10660 Park Rd Ste 4100, Charlotte, NC 28210 Phone: 704-541-8207 Fax: 704-540-8288 | |
Dr. Lawrence Andrew Eskew, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 335 N Caswell Rd, Charlotte, NC 28204 Phone: 704-384-7980 Fax: 704-384-7985 |